Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Merck
Covington
Medtronic
Daiichi Sankyo
Cantor Fitzgerald
Colorcon
Farmers Insurance

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202088

« Back to Dashboard

NDA 202088 describes SUPRENZA, which is a drug marketed by Citius Pharms and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the SUPRENZA profile page.

The generic ingredient in SUPRENZA is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
Summary for 202088
Tradename:SUPRENZA
Applicant:Citius Pharms
Ingredient:phentermine hydrochloride
Patents:2
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength15MG
Approval Date:Jun 13, 2011TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Jul 23, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Mar 14, 2029Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength30MG
Approval Date:Jun 13, 2011TE:RLD:No
Patent:➤ Try a Free TrialPatent Expiration:Jul 23, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 202088

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKinsey
Mallinckrodt
Deloitte
Farmers Insurance
Covington
Boehringer Ingelheim
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.